Category: Finance
Fifteen analysts provided mixed ratings for Blueprint Medicines, with an average 12-month price target of $116.47, reflecting an 18.93% increase from the previous target. Analysts' evaluations indicate a positive revenue trend, strong financial metrics, and a prudent debt management strategy, positioning the company favorably in the biopharmaceutical sector.
Keywords: Blueprint Medicines, analyst ratings, biopharmaceuticals
Update At: 8/5/2024